Regulatory role of TIPE2 by inhibiting microglial pyroptosis and glycolysis in the treatment of sepsis‐associated encephalopathy
Clinical and Translational Medicine · 2026-11 · 16 (11)
DOI: 10.1002/ctm2.70881 ↗Abstract
Abstract Background Sepsis_associated encephalopathy (SAE) denotes acute cerebral dysfunction triggered by sepsis and is accompanied by high mortality. Our previous study showed that TIPE2 significantly ameliorated cognitive impairment in SAE mice by inhibiting neuroinflammation, but the specific mechanism was unknown. Methods TIPE2 expression and cell specificity were analysed by scRNA‑seq and immunofluorescence. To establish SAE, cecal ligation and puncture (CLP) was carried out in TIPE2 knockout (KO) and WT mice. Neuronal/synaptic damage was assessed by TUNEL and TEM; cognitive function by behavioural tests and EEG. Hippocampal scRNA‑seq compared WT and TIPE2 KO mice. In vitro, primary microglia and BV2 cells were stimulated with LPS/nigericin. Protein expression (Western blot/IF), RhoA activation (GST‑pulldown), glucose/lactate levels, ROS production, and TIPE2‑RhoA interaction (Co‑IP/confocal) were examined. Results scRNA‑seq confirmed that TIPE2 is predominantly expressed in microglia and downregulated in SAE; its deficiency promotes pro‑inflammatory microglia associated with pyroptosis and glycolysis. TIPE2 KO significantly aggravated cognitive impairment, promoted M1 polarisation, enhanced pyroptosis (GSDMD cleavage, caspase‑1 activation), and increased ROS production. Mechanistically, TIPE2 directly bound to RhoA and inhibited its activation, thereby suppressing NLRP3‑mediated pyroptosis and glycolysis in microglia. Treatment with the RhoA‑specific inhibitor Rhosin reversed TIPE2 deficiency‑induced microglial polarisation, pyroptosis, ROS production, and glycolytic reprogramming, and also ameliorated cognitive dysfunction in TIPE2 KO mice. Conclusions TIPE2 protects against SAE by directly interacting with RhoA, inhibiting its activation, and subsequently suppressing NLRP3‑mediated microglial pyroptosis and glycolysis.
EUVIMED